Stable IgG-like bispecific antibodies directed toward the type I insulin-like growth factor receptor demonstrate enhanced ligand blockade and anti-tumor activity - Wikidata - wikimedia - TriplyDB

Stable IgG-like bispecific antibodies directed toward the type I insulin-like growth factor receptor demonstrate enhanced ligand blockade and anti-tumor activity

Stable IgG-like bispecific antibodies directed toward the type I insulin-like growth factor receptor demonstrate enhanced ligand blockade and anti-tumor activity

http://www.wikidata.org/entity/Q34575855

about

A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties.Evaluation of a novel hexavalent humanized anti-IGF-1R antibody and its bivalent parental IgG in diverse cancer cell lines Rapid optimization and prototyping for therapeutic antibody-like molecules.Bispecific antibody generated with sortase and click chemistry has broad antiinfluenza virus activity A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity HER-3 peptide vaccines/mimics: Combined therapy with IGF-1R, HER-2, and HER-1 peptides induces synergistic antitumor effects against breast and pancreatic cancer cells Fab-based bispecific antibody formats with robust biophysical properties and biological activity Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics Engineering the variable region of therapeutic IgG antibodies.Emerging antibody combinations in oncology.Dual targeting strategies with bispecific antibodies.New horizons in therapeutic antibody discovery: opportunities and challenges versus small-molecule therapeutics.Production of bispecific antibodies in "knobs-into-holes" using a cell-free expression system Novel multispecific heterodimeric antibody format allowing modular assembly of variable domain fragments.Protein design of IgG/TCR chimeras for the co-expression of Fab-like moieties within bispecific antibodies.The making of bispecific antibodies 6th Annual European Antibody Congress 2010: November 29-December 1, 2010, Geneva, Switzerland.Rational engineering of antibody therapeutics targeting multiple oncogene pathways.

P2860

Q33846405-86C76E9A-C6A9-4081-8EE9-EB360E3D19BE Q34406479-2862B319-13D3-4308-AA36-FBEBC87AA2C9 Q34580658-A117B692-4A9B-43EC-A3B0-49385B89CA84 Q34601167-CDC5B5A9-3940-491B-8492-1BC3228A0033 Q35146077-0EAD46DD-6D3B-43ED-8A04-885DB8AD6A02 Q35201923-ABAFCFE3-0E71-443B-80B2-1CC48EA27F57 Q36213193-7C61A595-7F33-42E0-9835-E66863A775AD Q36216009-463D93C4-C958-4C9E-AAF7-3512657404FA Q37853324-121A2E6D-51FE-47A1-B62E-DCC20A454A5F Q37893414-43E2F4A8-F2A6-4870-A2C1-0C0FAD652B32 Q37997559-742B0673-D113-4983-9B97-102CAE3DA12E Q38289992-C96BB47C-BBD3-4A8E-BD70-B89C54E6F05F Q41647084-F721428B-7011-4D29-B674-79B44579988C Q41837643-3961B65F-110D-4AD8-AAFC-CB17D05B7908 Q41838529-08CED053-1F52-40A6-89CE-EC376676F4B8 Q42323236-4058F7A5-9158-4FB3-A5AB-5C37DBC5F87C Q42732008-8EC79783-01EB-4D5C-9D61-FD86DAE03E07 Q42854245-34E61E12-3479-42A7-98A9-A17BD7159748

P2860

Stable IgG-like bispecific antibodies directed toward the type I insulin-like growth factor receptor demonstrate enhanced ligand blockade and anti-tumor activity

http://www.wikidata.org/entity/Q34575855

description

2010 nî lūn-bûn

@nan

2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

name

Stable IgG-like bispecific ant ...... ockade and anti-tumor activity

@ast

Stable IgG-like bispecific ant ...... ockade and anti-tumor activity

@en

Stable IgG-like bispecific ant ...... ockade and anti-tumor activity

@nl

type

label

Stable IgG-like bispecific ant ...... ockade and anti-tumor activity

@ast

Stable IgG-like bispecific ant ...... ockade and anti-tumor activity

@en

Stable IgG-like bispecific ant ...... ockade and anti-tumor activity

@nl

prefLabel

Stable IgG-like bispecific ant ...... ockade and anti-tumor activity

@ast

Stable IgG-like bispecific ant ...... ockade and anti-tumor activity

@en

Stable IgG-like bispecific ant ...... ockade and anti-tumor activity

@nl

P1433

Q34575855-FE928C2C-974B-47D2-9F54-7F328E81A52F

P1476

Q34575855-0D787DC5-A6CB-4D5B-8C7B-DCDA0C9D253E

P2093

Q34575855-0ADA37B1-622D-416E-A796-D394C4EB196D

Q34575855-0D885624-518B-4A5E-BF56-978DA4BCE240

Q34575855-17B13673-D89C-4344-A6A3-022502893C72

Q34575855-1ABC56F1-C652-4E1D-8B2D-A0E81219E945

Q34575855-1C105936-654F-4189-BF3D-E1148982A53A

Q34575855-3291A8FF-D45A-4542-92AB-B5A493838178

Q34575855-3E3D2136-8376-4E3D-86BB-D8C3F8EC26DA

Q34575855-417AD451-7C65-4ADE-99CC-34901AC539A0

Q34575855-54EAC1A6-1FAB-4121-AE89-5999578143F9

Q34575855-55BB3E2C-FBC2-4C99-9294-E9A8532F78FB

P2860

Q34575855-0386FE91-853D-419E-B7B0-390C611501FE

Q34575855-0C1AF253-8584-49E2-820D-555CD8845115

Q34575855-0E936EF7-E1A9-491B-BE98-652ACA3A3F6D

Q34575855-167C73C1-556F-402B-9CCF-34704AAE7670

Q34575855-1B495E5E-622D-444D-AF50-2C6DDD514922

Q34575855-2FC8230C-2A93-4213-984D-D43F240A1AAD

Q34575855-358D14F0-9E15-41B3-AC38-A980A3FC14E8

Q34575855-3644824B-AD35-4E7C-83FC-77951155009F

Q34575855-392D3799-6889-4139-B856-5559F0B424AF

Q34575855-3B7D7812-657F-4571-B3E6-EDE89572825C

P304

Q34575855-D506371C-0ACC-4D8B-B988-6AE72B6B2C83

P31

Q34575855-649B3523-D26F-4B4C-A68E-D462CCCB2219

P356

Q34575855-5CFC2248-A609-4886-8A8D-72CEA650E71C

P407

Q34575855-0A0FA179-C5B7-4349-9918-8D2FC628A256

P433

Q34575855-B0FB60B4-60EB-4047-BF10-84AD9D650171

P478

Q34575855-432F772E-4F5C-4877-97D9-360366447BBD

P577

Q34575855-9F3FCB51-0E2B-4D48-9B48-F5B185E04D58

P698

Q34575855-0209F53F-1A7E-4738-9523-5B38336B35DE

P921

Q34575855-9A916504-9BF4-4DCD-8296-DCFEDD42C1C3

P932

Q34575855-1B9ED409-ED3F-40BF-8906-46E678B28152

P356

JBC.M110.184317

P1433

Journal of Biological Chemistry

P1476

Stable IgG-like bispecific ant ...... ockade and anti-tumor activity

@en

P2093

Adam Doern

http://www.w3.org/2001/XMLSchema#string

Alexey Lugovskoy

http://www.w3.org/2001/XMLSchema#string

Antonio Boccia

http://www.w3.org/2001/XMLSchema#string

Arlene Sereno

http://www.w3.org/2001/XMLSchema#string

Brian R Miller

http://www.w3.org/2001/XMLSchema#string

Emma Langley

http://www.w3.org/2001/XMLSchema#string

Flora Huang

http://www.w3.org/2001/XMLSchema#string

Gisela Chiang

http://www.w3.org/2001/XMLSchema#string

Heather Gouvis

http://www.w3.org/2001/XMLSchema#string

Hon Tran

http://www.w3.org/2001/XMLSchema#string

P2860

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

Comprehensive analysis of the factors contributing to the stability and solubility of autonomous human VH domains

Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site

Structural understanding of stabilization patterns in engineered bispecific Ig-like antibody molecules

Tumor regression in cancer patients by very low doses of a T cell-engaging antibody

Insulin and insulin-like growth factor signalling in neoplasia

Stability engineering of antibody single-chain Fv fragments.

Engineering stability into Escherichia coli secreted Fabs leads to increased functional expression.

Antibody therapeutics, antibody engineering, and the merits of protein stability.

Characterization of inhibitory anti-insulin-like growth factor receptor antibodies with different epitope specificity and ligand-blocking properties: implications for mechanism of action in vivo.

P304

4703-4717

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1074/JBC.M110.184317

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

286

http://www.w3.org/2001/XMLSchema#string

P577

2010-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21123183

http://www.w3.org/2001/XMLSchema#string

P921

P932

3039382

http://www.w3.org/2001/XMLSchema#string